The promise of mRNA extends far beyond the current pandemic

摘要

A COLLECTIVE wave of excitement swept around the world when Pfizer and BioNTech announced positive early results from their coronavirus vaccine trial last week. Now, biotechnology firm Modema has announced even better findings (see page 7). These are no ordinary vaccines: they could be the first messenger RNA (mRNA) vaccines to be approved. If this technology lives up to its promise, it could bring huge benefits for healthcare, not just for tackling the coronavirus.